MX382453B - Composiciones y metodos para tratar enfermedades neurodegenerativas - Google Patents

Composiciones y metodos para tratar enfermedades neurodegenerativas

Info

Publication number
MX382453B
MX382453B MX2016012645A MX2016012645A MX382453B MX 382453 B MX382453 B MX 382453B MX 2016012645 A MX2016012645 A MX 2016012645A MX 2016012645 A MX2016012645 A MX 2016012645A MX 382453 B MX382453 B MX 382453B
Authority
MX
Mexico
Prior art keywords
compositions
methods
neurodegenerative diseases
treating neurodegenerative
disease
Prior art date
Application number
MX2016012645A
Other languages
English (en)
Other versions
MX2016012645A (es
Inventor
Michael J Brownstein
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of MX2016012645A publication Critical patent/MX2016012645A/es
Publication of MX382453B publication Critical patent/MX382453B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se describen compuestos y composiciones, m?todos y usos de los mismos, para tratar trastornos y enfermedades neurodegenerativas. En particular, se describen moduladores de receptores de vasopresina, y composiciones, m?todos y usos de los mismos para tratar aspectos neuro-psiquiatricos de enfermedades neurodegenerativas tal como enfermedad de Huntington, enfermedad de Parkinson, y enfermedad de Alzheimer.
MX2016012645A 2014-03-28 2015-03-27 Composiciones y metodos para tratar enfermedades neurodegenerativas MX382453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28
PCT/US2015/023060 WO2015148962A1 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
MX2016012645A MX2016012645A (es) 2017-01-11
MX382453B true MX382453B (es) 2025-03-13

Family

ID=54196457

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021005502A MX2021005502A (es) 2014-03-28 2015-03-27 Composiciones y metodos para tratar enfermedades neurodegenerativas.
MX2016012645A MX382453B (es) 2014-03-28 2015-03-27 Composiciones y metodos para tratar enfermedades neurodegenerativas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021005502A MX2021005502A (es) 2014-03-28 2015-03-27 Composiciones y metodos para tratar enfermedades neurodegenerativas.

Country Status (22)

Country Link
US (4) US9802925B2 (es)
EP (1) EP3122743B1 (es)
JP (2) JP7255967B2 (es)
KR (2) KR20160130853A (es)
CN (3) CN116327950A (es)
AU (2) AU2015237253B2 (es)
BR (1) BR112016022575A2 (es)
CA (1) CA2944211C (es)
DK (1) DK3122743T3 (es)
ES (1) ES2939959T3 (es)
FI (1) FI3122743T3 (es)
IL (1) IL248074B (es)
MX (2) MX2021005502A (es)
MY (1) MY184878A (es)
NZ (1) NZ724718A (es)
PL (1) PL3122743T3 (es)
RU (1) RU2742773C2 (es)
SG (2) SG10202001065SA (es)
SI (1) SI3122743T1 (es)
TW (2) TWI839623B (es)
WO (1) WO2015148962A1 (es)
ZA (1) ZA201606673B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
TWI622380B (zh) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 生理訊號測量裝置及其血氧濃度演算方法
MX2020002762A (es) * 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
JP2024501257A (ja) * 2020-12-23 2024-01-11 セルジーン コーポレーション 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
EP0655055B1 (en) 1992-08-13 2000-11-29 Warner-Lambert Company Tachykinin antagonists
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
ATE158580T1 (de) 1993-05-06 1997-10-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
CA2246753C (en) 1996-02-23 2005-05-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
ATE277050T1 (de) 1997-07-30 2004-10-15 Wyeth Corp Trizyclische vasopressin agoniste
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
PL193086B1 (pl) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
DK1206261T3 (da) 1999-08-16 2006-07-03 Revaax Pharmaceuticals Llc Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
AU2002342045C1 (en) 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
US20060281728A1 (en) 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
PL1910346T3 (pl) 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
US20100016274A1 (en) 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US7825111B2 (en) 2006-09-22 2010-11-02 Janssen Pharmaceutica Nv Substituted spiroheterocycles
EP2173745A2 (en) 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
US20090182011A1 (en) * 2008-01-16 2009-07-16 University Of Illinois Chicago Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.

Also Published As

Publication number Publication date
EP3122743B1 (en) 2022-11-09
JP2017510645A (ja) 2017-04-13
CN116327950A (zh) 2023-06-27
MX2016012645A (es) 2017-01-11
PL3122743T3 (pl) 2023-05-02
KR20160130853A (ko) 2016-11-14
MX2021005502A (es) 2023-01-16
JP7255967B2 (ja) 2023-04-11
JP2022116001A (ja) 2022-08-09
SG11201608064WA (en) 2016-10-28
AU2019253831B2 (en) 2021-10-28
EP3122743A1 (en) 2017-02-01
CN106459021B (zh) 2023-04-07
DK3122743T3 (da) 2023-02-20
ZA201606673B (en) 2019-06-26
US9802925B2 (en) 2017-10-31
IL248074B (en) 2020-07-30
RU2016138349A (ru) 2018-05-04
IL248074A0 (en) 2016-11-30
TWI736519B (zh) 2021-08-21
SG10202001065SA (en) 2020-04-29
US11319306B2 (en) 2022-05-03
US20200102294A1 (en) 2020-04-02
AU2015237253B2 (en) 2019-11-14
WO2015148962A1 (en) 2015-10-01
TWI839623B (zh) 2024-04-21
CA2944211C (en) 2022-10-04
RU2742773C2 (ru) 2021-02-10
US20170174670A1 (en) 2017-06-22
ES2939959T3 (es) 2023-04-28
RU2016138349A3 (es) 2018-10-26
US10364236B2 (en) 2019-07-30
KR20220151037A (ko) 2022-11-11
TW202216702A (zh) 2022-05-01
FI3122743T3 (fi) 2023-03-02
AU2019253831A1 (en) 2019-11-14
CN116139282A (zh) 2023-05-23
US20180201608A1 (en) 2018-07-19
SI3122743T1 (sl) 2023-07-31
AU2015237253A1 (en) 2016-10-20
NZ724718A (en) 2023-04-28
BR112016022575A2 (pt) 2017-08-15
CA2944211A1 (en) 2015-10-01
CN106459021A (zh) 2017-02-22
EP3122743A4 (en) 2017-11-29
MY184878A (en) 2021-04-29
TW201620902A (zh) 2016-06-16
US20230123729A1 (en) 2023-04-20
KR102725123B1 (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
NZ737399A (en) Ccr2 modulators
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
TW201613901A (en) New compounds
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691541A1 (ru) Новые анти-baff антитела
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201990400A1 (ru) Соединения и композиции и их применение
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX378940B (es) Trastornos neurodegenerativos.
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EA202090414A1 (ru) Соединения и их применение
MX394123B (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso
EA201790893A1 (ru) Способы лечения офтальмологических расстройств